Clinical Edge Journal Scan

Microcalcifications and high breast density increase risk for breast cancer


 

Key clinical point: Microcalcifications and breast density, as assessed by the Breast Imaging Reporting and Data System 4th edition (BI-RADS) were associated with a significantly increased risk for breast cancer (BC).

Major finding: Microcalcification appeared to be a significant risk factor for BC irrespective of breast density (adjusted hazard ratio [aHR] 3.09; 95% CI 2.83-3.36). Both microcalcification and high breast density (BI-RADS density classification 4) were associated with a 6.65-fold (95% CI 5.59-7.72) higher risk for BC, with the risk being the highest in postmenopausal women with microcalcifications and high breast density (aHR 7.26; 95% CI 5.01-10.53).

Study details: Findings are from a retrospective cohort study including 3,910,815 women who underwent breast cancer screening, of which 58,315 women were diagnosed with BC during a median follow-up of 10.8 years.

Disclosures: This study was supported by the National Research Foundation of Korea and other sources. The authors declared no conflicts of interest.

Source: Kim S et al. Microcalcifications, mammographic breast density, and risk of breast cancer: A cohort study. Breast Cancer Res. 2022;24:96 (Dec 21). Doi: 10.1186/s13058-022-01594-0

Recommended Reading

3D-printed tumor models could advance new cancer therapies
MDedge Hematology and Oncology
Canadian guidance recommends reducing alcohol consumption
MDedge Hematology and Oncology
HR+/ERBB2+ BC: Endocrine therapy-containing first-line regimens show benefits even without chemotherapy
MDedge Hematology and Oncology
Adding ovarian function suppression to adjuvant endocrine therapy beneficial in HR+ BC
MDedge Hematology and Oncology
Early BC: No effect on survival outcomes with less frequent adjuvant zoledronate infusions
MDedge Hematology and Oncology
HER2+ BC: Adding pyrotinib to neoadjuvant trastuzumab+docetaxel shows promise in phase 3 study
MDedge Hematology and Oncology
HER2 expression has no impact on prognosis in metastatic TNBC
MDedge Hematology and Oncology
Improved survival with systemic treatment+local ablative therapy in oligometastatic BC
MDedge Hematology and Oncology
HER2+ metastatic BC: Meta-analysis demonstrates superior efficacy of pyrotinib over lapatinib
MDedge Hematology and Oncology
Breast cancer: Nipple-sparing mastectomy after neoadjuvant chemotherapy is oncologically safe
MDedge Hematology and Oncology